PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för dasatinib (anhydrous). Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

14 hits

Bibliografisk träff 2012-10-12

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells.

Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP.

Haematologica · research-article; journal article · DOI 10.3324/haematol.2012.070268

Bibliografisk träff 2012-09-20

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.

Santos FP, Cortes J.

Expert Opin Pharmacother · review; journal article · DOI 10.1517/14656566.2012.725722

Bibliografisk träff 2012-03-12

Dasatinib inhibits proinflammatory functions of mature human neutrophils.

Futosi K, Németh T, Pick R, Vántus T, Walzog B, Mócsai A.

Blood · research support, non-u.s. gov't; research-article; journal article · DOI 10.1182/blood-2011-07-369041

Bibliografisk träff 2012-01-20

Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo.

Chan D, Tyner JW, Chng WJ, Bi C, Okamoto R, Said J, Ngan BD, Braunstein GD, Koeffler HP.

Oncol Lett · research-article; journal article · DOI 10.3892/ol.2012.579

Bibliografisk träff 2011-04-01

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets · research support, non-u.s. gov't; review; journal article · DOI 10.2174/138945011794751591

Bibliografisk träff 2009-07-28

Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.

Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P.

Leuk Res · review; journal article; case reports · DOI 10.1016/j.leukres.2009.07.009

Bibliografisk träff 2009-06-03

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

Gratacap MP, Martin V, Valéra MC, Allart S, Garcia C, Sié P, Recher C, Payrastre B.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2009-02-205328

Bibliografisk träff 2009-06-01

Practical management of dasatinib for maximum patient benefit.

Galinsky I, Buchanan S.

Clin J Oncol Nurs · review; journal article · DOI 10.1188/09.cjon.329-335

Bibliografisk träff 2008-09-29

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N.

J Transl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1479-5876-6-53

Bibliografisk träff 2008-09-16

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

Chang Q, Jorgensen C, Pawson T, Hedley DW.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjc.6604676

Bibliografisk träff 2008-09-11

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.

Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ.

Leukemia · letter; research support, non-u.s. gov't · DOI 10.1038/leu.2008.237

Bibliografisk träff 2007-11-01

Management of Bcr-Abl-positive leukemias with dasatinib.

Hochhaus A.

Expert Rev Anticancer Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/14737140.7.11.1529

Bibliografisk träff 2006-11-01

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.

Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV, Shen Z, Cook LS, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, McIntyre KW, Shuster DJ, Gillooly KM, Behnia K, Schieven GL, Wityak J, Barrish JC.

J Med Chem · journal article · DOI 10.1021/jm060727j

Bibliografisk träff 2006-06-01

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med · research support, non-u.s. gov't; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1056/nejmoa055229